Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is poised for long-term success with their diverse product portfolio, strong revenue growth potential, and focus on the pharmacy sales channel. Despite short-term challenges, their pipeline of new products, such as the Mobi Tubeless insulin pump, showcase their commitment to innovation and potential for continued market dominance. With a clear strategy and strong financials, Tandem Diabetes Care is a promising company with a positive outlook for the future.

Bears say

Tandem Diabetes Care is facing several headwinds, including a challenging competitive landscape, limited traction with new product launches, and potential switch-outs of existing patients from its pumps. The company's transition to a pay-as-you-go ("Pay-Go") model in the pharmacy channel could also impede its scale and profitability. Additionally, the success of their new Mobi pump may take longer than expected to materialize, which could hinder their profit expansion. Risks to the downside include possible competitive headwinds and limited traction with new product launches, as well as the company's ability to secure favorable contracts in the pharmacy channel. On the upside, Tandem may see success with accessing the pharmacy channel and can play more offense with new product cycles, which could lead to greater market share and faster profit growth. However, the company's outlook for 2026 and beyond remains uncertain due to potential headwinds and uncertainties surrounding their new product launches and pay-as-you-go model.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.